IMB-R1 differs from other existing FGFR1-neutralizing antibodies in that it expressly disrupts HS-FGFR1 interactions, highlighting the importance of targeting heparin-binding sites as a potential anti-cancer strategy. This evidence concerns the gene FGFR1 and cancer.